|Bid||8.35 x 4000|
|Ask||8.44 x 4000|
|Day's Range||8.32 - 8.97|
|52 Week Range||6.26 - 13.91|
|Beta (5Y Monthly)||2.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.67|
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
Despite the pharmaceutical industry’s best efforts, its least-favorite plan to cut drug prices isn’t going away. Unrest over drug pricing hung like a shadow above this year’s J.P. Morgan Health Care conference.
After many years of fits & starts, 2020 will be the right year for Sangamo Therapeutics (SGMO), my top speculative idea for 2020, suggests John McCamant, biotech stock expert and editor of The Medical Technology Stock Letter.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present a corporate overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16th at 8:30 a.m. PT in San Francisco.
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND). Pfizer is advancing SB-525 into a Phase 3 registrational clinical study in 2020 and has already commenced enrolling patients into a Phase 3 lead-in study. Sangamo has now earned a $25 million milestone payment, per the terms of a December 2019 amendment to the parties’ collaboration agreement for the global development and commercialization of gene therapies for Hemophilia A.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, is hosting an R&D Day today beginning at 8am Eastern Time. During the event, Sangamo executives and scientists plan to provide updates across the Company’s clinical and preclinical pipeline, as well as an overview of manufacturing capabilities to support clinical and commercial supply. A live webcast link will be available on the Events and Presentations page of the Sangamo website
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating investigational ST-400 ex vivo gene-edited cell therapy in transfusion-dependent beta thalassemia (TDT). The data are featured in a poster presentation on December 9, 2019 at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. The ST-400 ASH poster will be available on Sangamo’s website in the Investors and Media section under Events and Presentations at the beginning of the poster session at 10am Eastern Time.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A. The data showed that SB-525 was generally well tolerated and demonstrated sustained increased Factor VIII (FVIII) levels following treatment with SB-525 through to 44 weeks, the extent of follow-up for the longest treated patient in the 3e13 vg/kg dose cohort. Data from 11 patients treated with SB-525 will be featured in a poster presentation today, December 7, 2019, at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. The SB-525 ASH poster, which includes the full set of data, is available on Sangamo’s website in the Investors and Media section under Events and Presentations.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the Company plans to host an R&D Day on December 17, 2019 at 8am Eastern Time in New York City. Sangamo executives and scientists will provide updates across the Company’s clinical and preclinical pipeline of genomic medicine product candidates, offer perspective on clinical data being presented at the upcoming American Society of Hematology Annual Meeting, and provide an overview of the Company’s manufacturing capabilities to support clinical and commercial supply.
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Gene therapy company Audentes Therapeutics Inc (NASDAQ: BOLD ) announced a deal late Monday to be acquired by Japanese pharma company ASTELLAS PHARMA/ADR (OTC: ALPMY ) for $60 per share, representing a ...
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, today announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial experience, to the Company's Board of Directors. "We are pleased that Jim has joined the Sangamo Board of Directors," said Sandy Macrae, Chief Executive Officer of Sangamo. Mr. Meyers has over 30 years of commercial leadership experience in the biotechnology industry and worked at Gilead from 1996 until his retirement in February 2018.
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
The company is in early stages of testing gene and cell therapies they hope will deliver 'transformative and curative' treatments Continue reading...
Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today that the United Kingdom’s (UK) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy. TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). Sangamo expects to open the first clinical sites for the STEADFAST study in 2020.
Sangamo Therapeutics, Inc. , a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m.